Evidation Shares Insights on Real-World GLP-1 Dosing Behaviors from Over 60,000 Individuals

New insights from Evidation’s cardiometabolic health and weight management cohort, comprised of over 160,000 individuals, show what factors shape real-world dosing decisions.

SAN MATEO, Calif.--(BUSINESS WIRE)--Evidation, the leader in direct-from-participant real-world data and health research, is announcing new preliminary insights suggesting that nearly 1 in 7 injectable GLP-1 users are microdosing, that microdosing is largely patient-driven, and that there are multiple relevant influences driving microdosing decisions.

Evidation has been conducting ongoing, multimodal, participant-consented research within a discrete cohort of over 160,000 individuals who are actively managing their weight and related health conditions. A significant subcohort of this group have ever tried or are currently on incretin therapies.

As part of this research cohort, Evidation deployed a survey to understand individuals’ experiences and perceptions with microdosing incretin therapies. Evidation collected over 60,000 responses in under two weeks. Survey responses reveal that incretin users are adapting dosage of injectable GLP-1 therapies to manage tolerability, reduce out-of-pocket costs, and mitigate the burden of long-term high-dose treatment. Additionally, these preliminary findings strongly suggest that these decisions occur outside clinical settings and are patient-driven versus provider-driven.

Key takeaways from Evidation’s microdosing survey of over 60,000 respondents include:

• Nearly 1 in 7 injectable GLP-1 users reported ever microdosing.
• The most common reasons for microdosing are to manage tolerability, reduce costs, and transition to weight maintenance.
• Social media is the primary source of information about microdosing for both those who are using standard dosing and those who are using microdosing strategies.
• About half of people who microdose started on a standard regimen before switching to microdosing.
• About half of people who microdose also report using compounded versions of GLP-1 medications.
• More than one-third of people who are currently microdosing are making dosing decisions on their own, without guidance from a provider.
• Nearly one-third of individuals who have never taken a GLP-1 expressed interest in microdosing, motivated by cost, concerns about potential muscle loss, and a desire for greater dose flexibility.

“Evidation’s microdosing survey reveals important aspects of real-world usage that are currently invisible through EHR or claims data. Microdosing is just one example of how the demand and market for metabolic therapies is larger, more varied, and more dynamic than what prescribing or billing data can show,” said Leslie Wilberforce, CEO, Evidation. “We believe this research is critical to ensuring that rapidly changing usage patterns are characterized, and that the next generation of metabolic therapies are truly patient centric.”

Evidation will be sharing more on these survey findings and its research cohorts at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12th-16th, 2026:

• Evidation will be hosting a reception and panel discussion, GLP-1s in the Wild, the evening of January 13th.
• Evidation Chief Medical Officer Sunny Khan, MBChB, MPH will be speaking on Wednesday, January 14th at Fierce JPM Week.

JPM attendees can book a meeting, or get in touch at [e-mail].

About Evidation’s Cardiometabolic Health and Weight Management Cohort

Evidation’s Cardiometabolic Health and Weight Management Cohort includes more than 160,000 individuals contributing longitudinal real-world data, including detailed experiences with anti-obesity medications, strategies, and programs. The cohort integrates patient-reported outcomes, continuous digital measures, and clinical data, and reflects a broad distribution of BMI profiles and cardiometabolic comorbidities. Retrospective data already collected can be augmented with rigorously designed prospective data collection to address emerging evidence needs.

About Evidation

Evidation is redefining real-world data through direct, interactive relationships with millions of individuals. Through continuous engagement, Evidation captures longitudinal data to provide a more complete picture of health, including patient-reported and functional outcomes, connected device data, permissioned clinical records, and biosamples. Its privacy-first platform supports a right person, right time approach to data collection, enabling faster research, stronger evidence, and better product decisions. Founded in 2012, Evidation is headquartered in California.